THERAPEUTIC CANCER TREATMENTS

• US 20090181997A1
• Filed: 12/23/2008
• Published: 07/16/2009
• Est. Priority Date: 12/27/2007
• Status: Abandoned Application

• Current Assignee: Infinity Pharmaceuticals, Inc.
• Original Assignee: Infinity Pharmaceuticals, Inc.
• Inventors: Ross, Robert, GRAYZEL, David, MacDougall, John
• Application Number:
  US12/343,245
• Publication Number:
  US 20090181997A1
• Time in Patent Office: Days
• US Class Current: 514/278
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/282 Platinum compounds
• CPC Class Codes: A61K 31/337 having four-membered rings, e.g. taxol
• CPC Class Codes: A61K 31/4355 the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
• CPC Class Codes: A61K 31/7068 having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
• CPC Class Codes: A61K 33/24 Heavy metals; Compounds thereof
• CPC Class Codes: A61K 33/243 Platinum; Compounds thereof
• CPC Class Codes: A61K 45/06 Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The invention is directed to use of hedgehog inhibitors in conjunction with chemotherapy in treating cancers, and preventing relapses thereby.

Claims

1. A method of extending relapse free survival in a cancer patient who is undergoing treatment with a chemotherapeutic, the method comprising administering a therapeutically effective amount of a hedgehog inhibitor to the patient.

2. The method of claim 1, wherein the hedgehog inhibitor is administered concurrently with the chemotherapeutic.

3. The method of claim 2, wherein administration of the hedgehog inhibitor continues after treatment with the chemotherapeutic has ceased.

4. The method of claim 1, wherein the hedgehog inhibitor is administered after treatment with the chemotherapeutic has ceased.

5. The method of claim 1, wherein the cancer is selected from lung cancer, bladder cancer, ovarian cancer, colon cancer, breast cancer, prostate cancer, multiple myeloma, acute myelogenous leukemia, and chronic myelogenous leukemia.

6. The method of claim 5, wherein the lung cancer is selected from small cell lung cancer and non-small cell lung cancer.

7. The method of claim 1, wherein the cancer is small cell lung cancer and the chemotherapeutic is selected from etoposide, carboplatin, cisplatin, irinotecan, topotecan, gemcitabine, radiation therapy, and combinations thereof.

8. The method of claim 1, wherein the cancer is non-small cell lung cancer and the chemotherapeutic is selected from vinorelbine, cisplatin, docetaxel, pemetrexed, etoposide, gemcitabine, carboplatin, bevacizumab, gefitinib, erlotinib, cetuximab, radiation therapy, and combinations thereof.

9. The method of claim 1, wherein the cancer is bladder cancer and the chemotherapeutic is selected from gemcitabine, cisplatin, methotrexate, vinblastin, doxorubicin, paclitaxel, docetaxel, pemetrexed, mitomycin C, 5-fluorouracil, radiation therapy, and combinations thereof.

10. The method of claim 1, wherein the cancer is ovarian cancer and the chemotherapeutic is selected from paclitaxel, docetaxel, carboplatin, gemcitabine, doxorubicin, topotecan, cisplatin, irinotecan, bevacizumab, radiation therapy, and combinations thereof.

11. The method of claim 1, wherein the cancer is colon cancer and the chemotherapeutic is selected from paclitaxel, 5-fluorouracil, leucovorin, irinotecan, oxaliplatin, capecitabine, bevacizumab, cetuximab, panitumumab, radiation therapy, and combinations thereof.

12. The method of claim 1, wherein the hedgehog inhibitor comprises a compound of formula I:

or a pharmaceutically acceptable salt thereof.

13. The method of claim 12, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

14. The method of claim 1, wherein the hedgehog inhibitor is administered as a pharmaceutical composition comprising the hedgehog inhibitor and a pharmaceutically acceptable excipient.

15. A method of extending relapse free survival in a cancer patient who had previously been treated with a chemotherapeutic, the method comprising administering a therapeutically effective amount of a hedgehog inhibitor to the patient after treatment with the chemotherapeutic has ceased.

16. The method of claim 15, wherein the cancer is selected from lung cancer, bladder cancer, ovarian cancer, colon cancer, acute myelogenous leukemia, and chronic myelogenous leukemia.

18. The method of claim 15, wherein the cancer is small cell lung cancer and the chemotherapeutic is selected from etoposide, carboplatin, cisplatin, irinotecan, topotecan, gemcitabine, radiation therapy, and combinations thereof.

19. The method of claim 15, wherein the cancer is non-small cell lung cancer and the chemotherapeutic is selected from vinorelbine, cisplatin, docetaxel, pemetrexed, etoposide, gemcitabine, carboplatin, bevacizumab, gefitinib, erlotinib, cetuximab, radiation therapy, and combinations thereof.

20. The method of claim 15, wherein the cancer is bladder cancer and the chemotherapeutic is selected from gemcitabine, cisplatin, methotrexate, vinblastin, doxorubicin, paclitaxel, docetaxel, pemetrexed, mitomycin C, 5-fluorouracil, radiation therapy, and combinations thereof.

21. The method of claim 15, wherein the cancer is ovarian cancer and the chemotherapeutic is selected from paclitaxel, docetaxel, carboplatin, gemcitabine, doxorubicin, topotecan, cisplatin, irinotecan, bevacizumab, radiation therapy, and combinations thereof.

22. The method of claim 15, wherein the cancer is colon cancer and the chemotherapeutic is selected from paclitaxel, 5-fluorouracil, leucovorin, irinotecan, oxaliplatin, capecitabine, bevacizumab, cetuximab, panitumumab, radiation therapy, and combinations thereof.

23. The method of claim 15, wherein the hedgehog inhibitor comprises a compound of formula I:

or a pharmaceutically acceptable salt thereof.

24. The method of claim 23, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

25. The method of claim 15, wherein the hedgehog inhibitor is administered as a pharmaceutical composition comprising the hedgehog inhibitor, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

17. The method of claim 17, wherein the lung cancer is selected from small cell lung cancer and non-small cell lung cancer.

26. A method of treating pancreatic cancer, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula I:

or a pharmaceutically acceptable salt thereof.

27. The method of claim 26, wherein the pharmaceutically acceptable salt is a hydrochloride salt.

28. The method of claim 26, wherein the compound of formula I is administered in combination with a chemotherapeutic.

29. The method of claim 28, wherein the chemotherapeutic is selected from gemcitabine, cisplatin, epirubicin, 5-fluorouracil, and combinations thereof.

30. The method of claim 28, wherein administration of the compound of formula I continues after treatment with the chemotherapeutic has ceased.

31. The method of claim 26, wherein the compound of formula I is administered as a pharmaceutical composition comprising the compound of formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

32. A method of treating cancer in a patient wherein the patient is undergoing other cancer therapy, the method comprising detecting elevated hedgehog ligand in the patient and administering a pharmaceutically effective amount of a hedgehog antagonist to the patient.

33. The method of claim 32, wherein the elevated hedgehog ligand is detected in blood, urine, circulating tumor cells, a tumor biopsy or a bone marrow biopsy.

34. The method of claim 32, wherein the step of detecting elevated hedgehog ligand comprises the steps of measuring hedgehog ligand in the patient prior to administration of the other cancer therapy, measuring hedgehog ligand in the patient after administration of the other cancer therapy, and determining if the amount of hedgehog ligand after administration of the other chemotherapy is greater than the amount of hedgehog ligand before administration of the other chemotherapy.

35. The method of claim 32, wherein the other cancer therapy is a chemotherapeutic.

36. A method of treating cancer in a patient, the method comprising identifying one or more chemotherapeutics that elevate hedgehog ligand expression in a tumor, and administering a therapeutically effective amount of the one or more chemotherapeutics that elevate hedgehog ligand expression in the tumor and a therapeutically effective amount of a hedgehog inhibitor.

37. The method of claim 36, wherein the step of identifying one or more chemotherapeutics that elevate hedgehog ligand expression in a tumor comprises the steps of exposing cells from the tumor to one or more chemotherapeutics in vitro, and measuring hedgehog ligand in the cells.